Abstract: Heparin in the blood is determined over a wide range of concentrations by measuring the clotting time of serum derived from a test specimen of blood when combined under standard conditions with thrombin and plasma solutions. The clotting time is then determined from an experimentally-established functional relationship between clotting time and heparin concentration.

Abstract: The combination of two tests, a procoagulant assay (PA) and a heparin-procoagulant assay (H-PA) makes it possible to determine the status of a patient with respect to thrombosis and whether a prethrombotic condition exists. The results of the tests can be used to determine whether and what type of treatment is necessary.

Abstract: A test for maladies which cause deviations in the rate of production of fibrinolytic enzymes is carried out by adding controlled quantities of standardized thrombin and fibrinogen solutions to a urine specimen and noting the clotting time. Shortening of the clotting time from that measured with urine from healthy subjects indicates that the quantity of fibrin degradation products (FDP) in the blood is below normal. Increased production of such FDP may be due to the presence of a blood clot, an embolism, severe liver disturbance, cancer, extensive myocardial infarction, or pancreatic inflammatory disease. Conversely, decreased production of said FDP is taken as indicating a condition presaging the formation of a blood clot, or a significant decrease in the rate of production of fibrinolytic enzymes. The detection of either type of deviation can be used as the basis for diagnosis and treatment.